| __timestamp | Alkermes plc | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 106352000 |
| Thursday, January 1, 2015 | 483393000 | 144969000 |
| Friday, January 1, 2016 | 519270000 | 162364000 |
| Sunday, January 1, 2017 | 567637000 | 188462000 |
| Monday, January 1, 2018 | 601826000 | 210850000 |
| Tuesday, January 1, 2019 | 693218000 | 240515000 |
| Wednesday, January 1, 2020 | 572904000 | 255497000 |
| Friday, January 1, 2021 | 603913000 | 298182000 |
| Saturday, January 1, 2022 | 218108000 | 349103000 |
| Sunday, January 1, 2023 | 253037000 | 366887000 |
| Monday, January 1, 2024 | 245331000 | 389335000 |
Unleashing insights
In the ever-evolving biotech industry, understanding cost dynamics is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Bio-Techne Corporation and Alkermes plc from 2014 to 2023. Over this period, Alkermes plc experienced a significant fluctuation, peaking in 2019 with a 39% increase from 2014, before a sharp decline in 2022. In contrast, Bio-Techne Corporation showed a steady upward trajectory, with costs rising by approximately 266% from 2014 to 2023. This divergence highlights differing strategic approaches and market conditions faced by these companies. Notably, the data for 2024 is incomplete, suggesting potential shifts in the coming year. Investors should consider these trends when evaluating the financial health and operational efficiency of these biotech giants.
Novo Nordisk A/S vs Alkermes plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Merck & Co., Inc. and Alkermes plc's Expenses
Amgen Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Gilead Sciences, Inc. and Bio-Techne Corporation's Expenses
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost of Revenue Trends: Biogen Inc. vs Alkermes plc
United Therapeutics Corporation vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Alkermes plc
Alkermes plc vs Veracyte, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses